The tests will help identify the inflammatory pathways involved in patients with COPD and asthma to help better guide therapy selection.
SAN ANTONIO, July 22, 2026--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
The institute said the advisory follows existing conduct rules, while Mahua Moitra accused it of curbing students' constitutional right to protest ...
Explore proteomics fundamentals, protein measurement, data interpretation and reproducibility to build confidence in ...
Although the COVID-19 pandemic has largely subsided, scientists continue to investigate why the virus proved so deadly, ...
Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per round The ...
Summary: Researchers demonstrated that the success of anti-CTLA-4 immunotherapy against brain tumors does not depend on local ...
For decades, medicine has chased a simple but elusive goal of delivering the right drug to the right place at the right time.
For decades, medicine has chased a simple but elusive goal of delivering the right drug to the right place at the right time.
Oak Brook, IL – Volume 40 of SLAS Discovery includes four original research articles covering innovative screening platforms and assay technologies ...
A team of researchers from Jilin University and other Chinese institutions has successfully sequenced the complete ...
Excalipoint Therapeutics and DP Technology announced a strategic collaboration to co-develop a proprietary AI agentic platform tailored for T-cell engager (TCE) and multi-specific antibody discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results